Literature DB >> 25202903

Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma.

D Wildner1, L Pfeifer1, R S Goertz1, T Bernatik2, J Sturm1, M F Neurath1, D Strobel1.   

Abstract

PURPOSE: In a prospective study, we compared the different perfusion kinetics of HCC and ICC using dynamic contrast-enhanced ultrasound (DCE-US).
MATERIALS AND METHODS: Patients with proven HCC and ICC were included. Three-minute video clips of CEUS examinations (CPS - low MI mode) after a bolus injection of 1.2 ml SonoVue were recorded and analyzed with quantification software (VueBox). Parameters for the arterial contrast enhancement [rise time (RT), time-to-peak (TTP)] towards portal venous contrast enhancement [mean transit time (local) (mTTl) and fall time (FT)] were quantified. Furthermore, contrast wash-out after peak enhancement (PE) (40 s, 80 s, 100 s and 120 s after PE) was compared between HCC and ICC.
RESULTS: 43 patients with proven HCC (n = 23 HCC; cirrhosis n = 16) and ICC (n = 20 ICC; Cirrhosis n = 6) were examined. No statistical difference of the arterial DCEUS parameters was found between HCC and ICC. Contrast enhancement of the portal venous and late phases showed significantly lower values in the ICC group indicating early wash-out of the contrast agent: mTTl (p = 0.0209): HCC 118.4 s (SD± 88.4); ICC 64.8 s (SD± 49.7). FT (p = 0.0433): HCC 42.5 s (SD± 27.7); ICC 27.7 s (SD± 16.2). The percental loss of intensity at a definite time point after PE was significantly higher in ICC than in HCC lesions.
CONCLUSION: DCE-US is able to detect and quantify differences in perfusion kinetics between HCC and ICC. Whereas arterial contrast enhancement patterns may overlap between HCC and ICC, a timed characterization of wash-out kinetics may offer an additional tool to characterize HCC and ICC. The presence of a rapid loss of signal intensity in the early portal venous phase is significantly higher in ICC than in HCC lesions. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25202903     DOI: 10.1055/s-0034-1385170

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  19 in total

Review 1.  Light and sound - emerging imaging techniques for inflammatory bowel disease.

Authors:  Ferdinand Knieling; Maximilian J Waldner
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.

Authors:  Barbara Schellhaas; Matthias Hammon; Deike Strobel; Lukas Pfeifer; Christian Kielisch; Ruediger S Goertz; Alexander Cavallaro; Rolf Janka; Markus F Neurath; Michael Uder; Hannes Seuss
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

3.  Single-center study: dynamic contrast-enhanced ultrasound in the diagnostic assessment of carotid body tumors.

Authors:  Vincent Schwarze; Constantin Marschner; Giovanna Negrao De Figueiredo; Michael Ingrisch; Johannes Rübenthaler; Dirk-André Clevert
Journal:  Quant Imaging Med Surg       Date:  2020-09

4.  High frame-rate contrast enhanced ultrasound (HIFR-CEUS) in the characterization of small hepatic lesions in cirrhotic patients.

Authors:  F Giangregorio; M Garolfi; E Mosconi; L Ricevuti; M G Debellis; M Mendozza; C Esposito; E Vigotti; D Cadei; D Abruzzese
Journal:  J Ultrasound       Date:  2022-10-13

5.  Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group.

Authors:  Andrej Lyshchik; Yuko Kono; Christoph F Dietrich; Hyun-Jung Jang; Tae Kyoung Kim; Fabio Piscaglia; Alexander Vezeridis; Juergen K Willmann; Stephanie R Wilson
Journal:  Abdom Radiol (NY)       Date:  2018-04

Review 6.  [Contrast-enhanced ultrasound (CEUS) and image fusion for procedures of liver interventions].

Authors:  E M Jung; D A Clevert
Journal:  Radiologe       Date:  2018-06       Impact factor: 0.635

7.  Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined?

Authors:  Hyo-Jin Kang; Jung Hoon Kim; Jeongin Yoo; Joon Koo Han
Journal:  Ultrasonography       Date:  2021-12-17

8.  Characterization of Focal Liver Lesions Indistinctive on B Mode Ultrasound: Benefits of Contrast-Enhanced Ultrasound.

Authors:  Yi Dong; Feng Mao; Jiaying Cao; Peili Fan; Wen-Ping Wang
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

9.  Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma.

Authors:  Feiqian Wang; Kazushi Numata; Masahiro Okada; Makoto Chuma; Hiromi Nihonmatsu; Satoshi Moriya; Akito Nozaki; Katsuaki Ogushi; Wen Luo; Litao Ruan; Masayuki Nakano; Masako Otani; Yoshiaki Inayama; Shin Maeda
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  An open source software for analysis of dynamic contrast enhanced magnetic resonance images: UMMPerfusion revisited.

Authors:  Frank G Zöllner; Markus Daab; Steven P Sourbron; Lothar R Schad; Stefan O Schoenberg; Gerald Weisser
Journal:  BMC Med Imaging       Date:  2016-01-14       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.